Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGICcell6: Angiopoietin-Primed Stem Cells in AMI
NCT06364150Phase 3
Key facts
- Status
- Recruiting
- Start
- Jul 2024
- Primary completion
- May 2025
- Countries
- 1
- Sponsor
- Seoul National University Hospital
- Modality
- Stem Cell Therapies
- Conditions
- acute myocardial infarction (AMI)
01
Overview
Phase 3, randomised trial of angiopoietin-primed autologous peripheral blood stem cells in acute myocardial infarction (AMI), sponsored by Seoul National University Hospital. Primary endpoint: Left ventricular systolic function at 12 months. Started Jul 2024; status: recruiting.
02
Design
1 arm- Study design
- Randomized
Cell treatment arm
Patients receive Angiopoietin-Primed Autologous Peripheral Blood Stem Cell injection
03
Who it enrols
Adult patients aged 19-80 with acute myocardial infarction within 4 weeks, successful PCI, and LVEF >= 20%. Excludes uncontrolled heart failure, arrhythmia, active malignancy, or infection.
04
Endpoints
Primary
Left ventricular systolic function
Secondary
Regional wall motion score index
B-natriuretic peptide level
6-minute walk test
All-cause death
Target lesion Revascularization
Readmission
Cardiovascular death
non-Target lesion Revascularization
Beyond the preview
Go deeper on NCT06364150.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364150.